profit from every $100 of sales.
$0$100
Arvinas
$6.76+5.46% today
-36.4% in 1 year
1-year low $6.411-year high $13.83
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Arvinas sold, what it kept, and what it did with the cash.
Sales went from $131 million in 2022 to $263 million in 2025, with -$80.8 million of profit last year.
SalesProfit
Arvinas vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Arvinas | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Arvinas's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 131 | 79 | 263 | 263 | |
| – | – | – | – | |
| -263 | -402 | -250 | -119 | |
| -255 | -395 | -244 | -113 | |
| -283 | -367 | -199 | -81 | |
| -5.31 | -6.62 | -2.77 | -1.14 | |
| – | – | – | – | |
| -200.3% | -511.5% | -95.0% | -45.1% | |
| -215.0% | -467.9% | -75.5% | -30.8% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,269 | 1,305 | 1,091 | 718 |
| Cash | 81 | 312 | 101 | 143 |
| Total debt | 6 | 3 | 10 | 9 |
| Total liabilities | 704 | 645 | 530 | 284 |
| 565 | 660 | 562 | 434 | |
| 53 | 56 | 72 | 71 | |
| -36.5% | -47.8% | -34.6% | -21.1% | |
| -50.0% | -55.7% | -35.4% | -18.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -274 | -348 | -259 | -274 | |
| 7 | 3 | 2 | 2 | |
| -280 | -351 | -261 | -276 | |
| Dividends paid | – | – | – | – |
| – | 0 | 0 | 92 | |
| 76 | 72 | 88 | 44 |
Valuation
- –
- –
- –
- 1.6×
- 1.7×
- –
- –
- -62.3%
- -18.3%
- 0.0%
Profitability
- 81.2%
- -45.1%
- -30.8%
- -261.6%
- -47.0%
- -36.5%
- -44.4%
- -34.2%
- -47.2%
- 284.9%
Growth
- +26.0%
- –
- −5.6%
- –
- +6.7%
Financial health
- -1.2×
- 0.02
- 1.3%
- –
- 5.44
- 5.44
- 0.14
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 9%of 948
Bottom 7%of 871
Top 22%of 868
Bottom 1%of 985
What analysts expect
- Average price target
- $13.00
- Range
- $10.00 – $18.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | -0.90 | -0.95 | +5.3% |
| Feb 24, 2026 | -1.10 | -0.55 | −100.0% |
| Nov 5, 2025 | -0.48 | -0.75 | +36.0% |
| Aug 6, 2025 | -0.84 | -0.87 | +3.4% |
| May 1, 2025 | 1.14 | -0.86 | +232.6% |
| Feb 11, 2025 | -0.63 | -1.07 | +41.1% |
| Oct 30, 2024 | -0.68 | -0.88 | +22.7% |
| Jul 30, 2024 | -0.49 | -0.72 | +31.9% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
38No pass
Benjamin Graham
61Pass
Philip Fisher
49No pass
Peter Lynch
73Pass
Joel Greenblatt
2No pass
Charlie Munger
36No pass
Terry Smith
42No pass
Questions about Arvinas
Is Arvinas a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Arvinas AI analysis
What does Arvinas do?
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. It is in Biotechnology.
Does Arvinas pay a dividend?
No. Arvinas does not pay a dividend at the moment; in 2025 it returned $91.9 million to shareholders by buying back its own shares.
Is Arvinas stock halal?
Questionable. Arvinas sits in a grey zone: its cash and confirmed interest-bearing investments are 32% of its market value, between 30% and 33%. How we check
How has Arvinas stock done over the past year?
Down 36.4% over the past twelve months, to $6.76. It traded between $6.41 and $13.83 and is 51.1% below its high.
Who are Arvinas's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Arvinas's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.